CRISPR-like technique offers clues to mimic protective genetic mutations
Using a variation of CRISPR gene editing may be a potential strategy for mimicking the protective effects of a genetic mutation linked to lower cholesterol levels and heart disease risks, according to new mouse research from the Perelman School of Medicine at the University of Pennsylvania published this week in Circulation.
People with naturally occurring mutations that cause a loss of function in the gene for ANGPTL3 have reduced blood triglycerides, LDL cholesterol, and risk of coronary heart disease, with no apparent detrimental consequences to their health. This makes the ANGPTL3 protein an attractive target for new heart disease drugs. Earlier studies at Penn found that single copies of inactivating mutations in ANGPTL3 are found in about one in every 250 people of European heritage; however, people with mutations in both copies of the gene are more rare.
A team led by Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine, assessed in a mouse model whether base editing – a variation of CRISPR genome editing that does not require breaks in the double-strand of DNA – might be used in humans one day to introduce mutations into ANGPTL3 to reduce blood lipid levels.
“This proof-of-principle study showed that base-editing of ANGPTL3 is a potential way to permanently treat patients with harmful blood lipid levels,” Musunuru said. “It would be especially useful in patients with a rare condition called homozygous familial hypercholesterolemia, which causes sky-high cholesterol levels and dramatically increased risk of heart attack. They are very difficult to treat with today’s medications, and a one-time CRISPR ‘vaccination’ might be ready to use in these patients within five years.”
The study took a three-part approach. First, the team injected normal mice with the base-editing treatment for the ANGPTL3 gene. After a week, sequencing of the ANGPTL3 target site in liver samples from the mice revealed a median 35 percent editing rate in the target gene and no off-target mutations. In addition, the mean levels of blood lipids were significantly lower in the treated mice by up to 30 percent compared to untreated mice.
Second, the researchers compared mice with the modified ANGPTL3 gene to those injected with a base-editing treatment for another liver gene, PCSK9, for plasma cholesterol and triglycerides. After a week, ANGPTL3 targeting caused a similar reduction in cholesterol but a much greater decline in triglycerides compared to targeting PCSK9. The PCSK9 protein is the target of currently available medications, including evinacumab, which has been shown to reduce cholesterol (but not triglycerides) as well as the risk of heart attack and stroke.
Third, they looked at how base editing of the ANGPTL3 gene performed in a mouse model of homozygous familial hypercholesterolemia (in which knocking out PCSK9 had little effect). After two weeks, the treated mice showed substantially reduced triglycerides (56 percent) and cholesterol (51 percent) compared to untreated mice.
Musunuru’s lab is now preparing to test CRISPR-based treatments against the human ANGPTL3 gene in human liver cells transplanted into mice. This will provide important information on efficacy and safety that will be needed before human trials can move forward.
The Latest on: Gene editing
[google_news title=”” keyword=”Gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene editing
- The future of cell and gene therapy manufacturingon November 30, 2023 at 11:00 pm
While the scope of cell and gene therapies continues to grow, experts gathered at the recent CPHI Europe 2023 conference were quick to note that manufacturing these treatments at the required scale ...
- Cibus Announces New Publication: Industrial Scale Gene Editing in Brassica napuson November 30, 2023 at 6:00 am
In the peer reviewed publication, the International Journal of Plant Biology, Cibusprovides two case studies of improving oleic oil content and ...
- Sickle cell disease: What newly approved gene editing therapy means for those afflicted in Indiaon November 30, 2023 at 2:17 am
CSIR scientist Debojyoti Chakraborty --- who is part of a team funded by the government to build a technology that would initiate a clinical trial for ...
- Gene Editing Market Size Worth USD 35.84 Billion in 2032 | Emergen Researchon November 30, 2023 at 12:22 am
Rising demand for synthetic genes in both developed and developing countries are major factors driving Gene Editing Gene Editing Market revenue growthVancouver, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The ...
- A Breakthrough in Gene Editingon November 29, 2023 at 7:51 am
A new CRISPR therapy is transforming the lives of sickle-cell patients. What could this mean for the technology’s future?
- What's Next For Gene-Editing Darling Crispr After Its 'Historic' First-Ever Approval?on November 29, 2023 at 5:04 am
Crispr just executed on a moonshot goal, winning U.K. approval for the first-ever gene-editing treatment and sending CRSP stock sky-high.
- CRISPR Gene Editing: Intellia Vs. Crispr Therapeuticson November 28, 2023 at 9:20 pm
NTLA focuses on in vivo gene editing and has a comprehensive pipeline targeting various genetic diseases and conditions. CRSP focuses on ex vivo gene editing and has a diverse pipeline targeting ...
- Decision looms for landmark gene-editing therapyon November 28, 2023 at 8:00 am
The FDA is expected to decide by the end of next week whether to approve the first gene-editing therapy in the U.S., just weeks after the treatment for a rare genetic blood disorder received ...
- Gene-Editing Breakthrough Tackles Rare Disorderon November 27, 2023 at 4:44 pm
Researchers have recently unveiled a potential treatment for a genetic disorder that affects one in every 50,000 people globally.
- An AI Tool Just Revealed Almost 200 New Systems for CRISPR Gene Editingon November 27, 2023 at 2:36 pm
The AI combed through hundreds of thousands of genomes from rare bacteria—including those found in breweries, coal mines, and dog saliva.
via Bing News